May 2025 in “The Journal of Rheumatology” Proactive physical therapy improved mobility, reduced fatigue, and pain in lupus patients.
2 citations
,
August 2020 in “Journal of Cosmetic Dermatology” Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
2 citations
,
October 2023 in “Frontiers in Public Health” Addressing psychosocial symptoms can improve outcomes for people with Hidradenitis Suppurativa.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
8 citations
,
June 2023 in “British Journal of Dermatology” The SAAD-41 scale effectively measures the psychosocial impact of alopecia areata.
September 2022 in “Journal of Investigative Dermatology” Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Patients with autoimmune blistering diseases experience a reduced quality of life, with the need for better measurement tools, especially for those with mucous membrane pemphigoid.
5 citations
,
February 2023 in “Skin Health and Disease” The Swedish Hairdex-S is a reliable tool for assessing quality of life in Alopecia Areata patients.
December 2013 in “Praxis medica” Using both DLQI and Skindex-16 together gives a better understanding of quality of life in skin disease patients.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
2 citations
,
April 2018 in “SLEEP” People with rheumatoid arthritis have poorer sleep quality than healthy individuals.
Lupus severely affects daily life, work, and mental health, with many experiencing frequent flares and medication side-effects.
24 citations
,
June 2021 in “Journal of the European Academy of Dermatology and Venereology” Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.
86 citations
,
January 2020 in “British Journal of Dermatology” The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.
Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.
9 citations
,
February 2018 in “Journal of Patient-Reported Outcomes” New tools were created to help lupus patients report their symptoms and impacts more accurately.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.